Biotech Startups Raised $9.1B in H1 2026, But Seed Funding Lagged

At least 68 venture-backed biotechnology companies banked more than $9.1 billion between January and June 2026, the highest first-half total since 2022, according to data compiled by BioPharma Dive across the 26 venture firms it tracks.

The headline number masks a widening gap. Two-thirds of the venture rounds in the first half — 42 in total — went to companies that already had a drug prospect in human testing, BioPharma Dive's data show. Capital for seed-stage startups and biotechs led by first-time founders remains far less abundant than it was five years ago, said Ashwin Singhania, a principal at Ernst & Young's life sciences practice.

"I think that a grave concern to the biotech community is where is that next wave of early innovation going to come from, especially with the backdrop of what happened at the NIH," Singhania said, referring to cuts to basic research funding that could have consequences for the U.S. drug industry as far as a decade down the line.

Mega-rounds did most of the lifting. About 76% of the total funds raised in the first half flowed through financings of $100 million or more, BioPharma Dive found. A single deal inflated the tally further: AI drug discovery specialist Isomorphic Labs raised a behemoth $2.1 billion round.

The momentum held despite headwinds. Venture capital has "continued to go strong" despite the threat of a U.S. government crackdown on investments in Chinese drug assets and turmoil at the Food and Drug Administration, said Ben Zercher, a senior analyst at research firm Pitchbook.

Strong public markets helped. Thirteen biotechs have raised a combined $4.5 billion in IPO proceeds so far in 2026, with a median haul of almost $302 million — unusually large by historical standards. Two companies, Parabilis Medicines and Kailera Therapeutics, broke sector records. Most of this year's debutantes now trade above their original share price.

M&A accelerated too. BioPharma Dive counts 38 acquisitions struck in 2026 so far, the sector's best acquisition pace in at least seven years. Almost two-thirds of those deals involved $1 billion or more in proceeds, and four topped $10 billion.

"The last few months have been reaffirming in terms of M&A," Simeon George, CEO and managing partner of venture firm SR One, said in a May interview. "Though IPOs have been a little more nuanced ... in the short term, the markets are a voting booth, and in the long term, they're weighing scales."

Investors are also concentrating on safer scientific bets. Immune and cancer-focused drugmakers accounted for more than 40% of first-half funding rounds. Developers of biologics and small molecules each raised more than $2 billion, dwarfing the totals secured by cell and gene therapy developers or nucleic acid-based therapy companies.

For cellular and genetic medicine makers, the first half extended a multi-year slump. They are on pace to raise about $2 billion in 2026, similar to most years since 2022.

Zercher pointed to the disappointing market performance of treatments like Casgevy, worrisome side effects seen in some clinical trials and "enhanced regulatory scrutiny" as reasons investors remain wary. "With all the turnover that's going on at the FDA, it creates a perfect storm of, 'maybe we just wait and see what's going on here before we size this bet on this market,'" he said.

Many companies attracting venture dollars in place of homegrown seed-stage startups are built around ready-made drug prospects licensed from China or elsewhere. Several, including cAMPfield Therapeutics and Solstice Oncology, launched this year. That flow of funding has sparked concerns about national security and market competition.

Still, the picture is one of selectivity rather than scarcity, said Doreen Levine, a partner at Ernst & Young's Americas life sciences sector accounting group. "For the right management team, with the right platform or asset, there could be an appetite [for investing]," Levine said. "The VCs have the liquidity and interest to do it, it's just that they're being very judicious."

The question hanging over the second half of 2026 is whether record megarounds and M&A can sustain the sector while the seed-stage pipeline — and the NIH-funded basic research that feeds it — continues to thin.